ClinicalTrials.gg
Not yet recruitingNCT06216444Updated Jan 22, 2024

A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures

A Phase 4 interventional study of Remimazolam Tosilate for Injection and Remimazolam Tosilate for Injection in Sedation in Non-intubated Diagnostic and Therapeutic Procedures, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in non-intubated diagnostic and therapeutic procedures

02

Conditions studied

  • Sedation in Non-intubated Diagnostic and Therapeutic Procedures
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old, male or female
  2. Intending to undergo routine gastroscopy or colonoscopy
  3. ASA () I to III
  4. 18 kg/m2≤ (Body Mass Index)≤30kg/m2
  5. Signed

Exclusion criteria

Exclusion Criteria:

  1. Subjects need to be tracheal intubation
  2. Subjects need to be complicated endoscopic diagnostic and therapeutic procedures
  3. Subjects who have had severe cardiovascular diseases or severe arrhythmias within 6 months prior to signing the ICF
  4. Heart rate \<50 beats/min during the screening period
  5. Poor blood pressure control during the screening period
  6. Subjects with severe respiratory diseases
  7. Subjects with respiratory management difficulties (Modified Mallampati grade IV)
  8. Subjects with a history of mental illness (schizophrenia, mania, bipolar disorder, psychosis, etc.), long-term use of psychotropic drugs, and cognitive impairment
  9. A history of drug abuse or addiction within 2 years prior to signing the ICF
  10. Pregnant women or those in lactation period
  11. Allergic to relevant drugs ingredient or component in the study
  12. Currently participating in or planning to participate in other drug or device clinical trials during this study
  13. Other conditions deemed unsuitable to be included
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Remimazolam Tosilate for Injection(5mg)

    Drug: Remimazolam Tosilate for Injection

  • Experimental
    Remimazolam Tosilate for Injection(10mg)

    Drug: Remimazolam Tosilate for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of sedation success, Sedation success

    Rate of sedation success, Sedation success is defined as: 1) Completion of the entire non-intubated diagnostic and therapeutic procedure; 2) No need for additional rescue sedation; 3) During the sedation induction phase, the MOAA/S score should be ≤3 within 2 minutes after the end of the initial dose administration or after ≤2 additional administrations; 4) No more than 2 additional administrations in every 5-minute.

    Time frame: day 1

Secondary outcomes

  1. Number of additional administrations.

    Time frame: day 1

  2. Percentage of subjects needing additional administration.

    Time frame: day 1

  3. One-time success rate of endoscope insertion during the diagnostic and therapeutic procedure.

    Time frame: day 1

  4. Rate of over-sedation.

    Time frame: day 1

  5. Sedation induction time

    Time frame: day 1

  6. Wake-up time.

    Time frame: day 1

  7. Time to discharge.

    Time frame: day 1

  8. Rate of sedation-related hypotension and rate of sedation-related hypotension needing treatment.

    Time frame: day 1

  9. Rate of respiratory depression during sedation.

    Time frame: day 1

  10. Investigator's Satisfaction with Sedation Assessment: The scoring range is from 0 to 10, where 0 represents dissatisfaction and 10 represents complete satisfaction.

    Time frame: day 1

  11. Participant's satisfaction with Sedation Assessment: The scoring range is from 0 to 10, where 0 represents dissatisfaction and 10 represents complete satisfaction.

    Time frame: day 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Mar 2024, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2023
First posted
Jan 22, 2024
StartEst.
Jan 2024
Primary completionEst.
Mar 2024
CompletionEst.
Mar 2024
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06216444
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Jan 2024 (estimated)
Primary completion
Mar 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
Jan 22, 2024

Study contacts

Qin Liu
Contact
qin.liu@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion